viewPressure BioSciences, Inc.

Pressure BioSciences' Ultra Sheer Technology featured in Cannabis Brightline magazine

The magazine, which has subscribers in the US and Canada, highlighted the potential uses for the technology, which extends the life of milk, and healthier drinks and juices

Magazines on a table
The Cannabis Brightline story titled, “The Solution for Maximizing the Bioavailability of CBD and Beyond” highlights demand for the company's Ultra Shear Technology

Pressure BioSciences Inc (OTCMKTS:PBIO) announced that its new Ultra Shear Technology (UST) platform was featured in Cannabis Brightline magazine.

The magazine, which has a base of thousands of subscribers in the US and Canada, highlighted the potential uses for the technology, which extends the life of milk, and healthier drinks and juices, by reducing heat exposure in the preservation process through a combined application of elevated pressure and controlled times and temperatures.

Ultra Shear Technology also utilizes high pressure to create intense, momentary liquid shearing forces at controlled temperatures that result in affordable and scalable homogenization of liquids, creams and gels.

READ: Pressure BioSciences's PCT platform featured in more than 20 scientific articles for second year in a row

Jason Ellis, President of Vegas CBD Factory and an expert in the manufacturing of cannabinoid-based products, was impressed.

"The article by Cannabis Brightline is very timely, as my colleagues in the cannabis market are now beginning to realize that top quality CBD products will only be generated from using high quality, water-soluble nanoemulsions of CBD oil,” Ellis said. Nanoemulsions created by processing CBD oil through PBI's UST platform provided astonishingly immediate and visually apparent water solubility, which years of science tells us will lead to greatly increased bioavailability. We are now considering the purchase of multiple Pressure BioSciences BaroShear K45 UST nanoemulsion systems in 2020."

The Cannabis Brightline story, titled “The Solution for Maximizing the Bioavailability of CBD and Beyond,” also discussed the potential uses for PBI’s other patented platforms and offered a summary of the work currently supported by the Massachusetts company’s pressure-based instruments.

CEO Richard Schumacher said the company is experiencing an influx of interest in its products.

"It has been very exciting to experience the rapidly growing increase in interest in our UST-based BaroShear K45 nanoemulsification system since the first of the year,” Schumacher said. “In just the past week, we have received nearly a dozen unsolicited phone calls/emails from individuals in North America and Europe. Many callers were aware that our initial build of 12 BaroShear K45 instruments is expected to begin in early 2020, and they wanted to ensure they could secure a spot on the initial build purchase list."

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Quick facts: Pressure BioSciences, Inc.

Price: 1.52 USD

Market: OTCQB
Market Cap: $5.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...


Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

2 min read